Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 7, 2026, 6:53 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 126 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Neurotoxicity Syndromes Clear all
Terminated Phase 3 Interventional Results available

D-cycloserine in the Management of Chemotherapy-Induced Peripheral Neuropathic Pain

NCT00301080
View directory record Official record
Conditions
Neurotoxicity, Pain, Breast Cancer
Interventions
D-cycloserine, Placebo
Drug · Other
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
2
States / cities
Chicago, Illinois • Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Dec 1, 2013 · Synced Sep 7, 2026, 6:53 PM EDT
Completed Not applicable Interventional

Study of Human Botulism Immunoglobulin in Infants With Botulism

NCT00004401
View directory record Official record
Conditions
Infant Botulism, Botulism
Interventions
botulism immune globulin
Drug
Lead sponsor
California Department of Health Services
Other
Eligibility
Up to 1 Year
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998
U.S. locations
1
States / cities
Berkeley, California
Source: ClinicalTrials.gov public record
Updated Mar 24, 2015 · Synced Sep 7, 2026, 6:53 PM EDT
Completed No phase listed Observational

The Platinum Study Comparison Group

NCT02890030
View directory record Official record
Conditions
Testicular Neoplasms
Interventions
Questionnaire
Behavioral
Lead sponsor
Lawrence Einhorn
Other
Eligibility
18 Years to 55 Years · Male only
Enrollment
102 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Apr 7, 2020 · Synced Sep 7, 2026, 6:53 PM EDT
Recruiting Not applicable Interventional

Multimodal Telerehabilitation in Patients Undergoing CAR-T Cell Immunotherapy

NCT07390071
View directory record Official record
Conditions
Lymphoma, Myeloma, Cytokine Release Syndrome, Immune Effector Cell Associated Neurotoxicity Syndrome
Interventions
Home Automated Telemanagement (HAT) Patient Unit
Device
Lead sponsor
University of Utah
Other
Eligibility
21 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Feb 4, 2026 · Synced Sep 7, 2026, 6:53 PM EDT
Terminated Phase 2 Interventional

Amifostine in Treating Women With Ovarian, Peritoneal, Cervical, Fallopian Tube, Uterine, or Endometrial Cancer

NCT00003624
View directory record Official record
Conditions
Cervical Cancer, Endometrial Cancer, Fallopian Tube Cancer, Neurotoxicity, Ovarian Cancer, Primary Peritoneal Cavity Cancer, Sarcoma
Interventions
amifostine trihydrate, cisplatin, paclitaxel
Drug
Lead sponsor
Gynecologic Oncology Group
Network
Eligibility
Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1998
U.S. locations
8
States / cities
Orange, California • Washington D.C., District of Columbia • Atlanta, Georgia + 5 more
Source: ClinicalTrials.gov public record
Updated Apr 10, 2013 · Synced Sep 7, 2026, 6:53 PM EDT
Active, not recruiting Phase 2 Interventional Results available

Bilirubin Neurotoxicity (BN) and Neurodevelopmental Impairment (NDI) in Extremely Preterm (EP) Infants: Avoidable by Reducing the Usual Intravenous Lipid (UL) Administration

NCT04584983
View directory record Official record
Conditions
Bilirubin Encephalopathy
Interventions
usual prescribed intralipid (UL) regimen, restricted prescribed intralipid (RL) regimen
Drug
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
Up to 27 Weeks
Enrollment
134 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Nov 27, 2025 · Synced Sep 7, 2026, 6:53 PM EDT
Withdrawn Phase 1Phase 2 Interventional

Pre-emptive Anakinra for Cytokine Event Reduction

NCT06703216
View directory record Official record
Conditions
B-Acute Lymphoblastic Leukemia, CAR-T Cell Therapy, Cytokine Release Syndrome, Immune Effector Cell Associated Neurotoxicity Syndrome, Immune Effector Cell Associated Hemophagocytic Lymphohistiocytosis-like Syndrome
Interventions
Anakinra (Kineret®)
Drug
Lead sponsor
Kevin McNerney
Other
Eligibility
1 Year to 25 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Aug 12, 2026 · Synced Sep 7, 2026, 6:53 PM EDT
Enrolling by invitation Phase 3 Interventional

Evaluating Cognitive Changes on Patients in Chemotherapy (ECCPC)

NCT06950190
View directory record Official record
Conditions
Chemotherapy-related Cognitive Impairment
Interventions
Low-Intensity Walking Intervention, Control Group Intervention
Behavioral
Lead sponsor
Ellis Medicine
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Schenectady, New York
Source: ClinicalTrials.gov public record
Updated Aug 11, 2025 · Synced Sep 7, 2026, 6:53 PM EDT
Completed Not applicable Interventional

Nerve Function in Older Diabetic Patients Who Are Undergoing Chemotherapy for Metastatic Solid Tumors

NCT00263861
View directory record Official record
Conditions
Neurotoxicity, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
management of therapy complications
Procedure
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
65 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 10, 2010 · Synced Sep 7, 2026, 6:53 PM EDT
Active, not recruiting Phase 2 Interventional

Cannabis Effects on Antiretroviral Therapy Pharmacokinetics and Neurotoxicity

NCT04800159
View directory record Official record
Conditions
HIV, Cannabis Use
Interventions
THC Cannabis, CBD Cannabis, Placebo
Drug
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Oct 14, 2025 · Synced Sep 7, 2026, 6:53 PM EDT
Withdrawn No phase listed Observational

Switching From One Type of Anti-rejection Drug (Tacrolimus or Cyclosporine) to Another (Sirolimus) Approximately 90-180 Days After Liver Transplantation

NCT00834496
View directory record Official record
Conditions
Side Effects of Calcineurin Inhibitors, Renal Toxicity, Hepatic Fibrosis on Biopsy, Neurotoxicity, Post Transplant Diabetes
Interventions
Liver biopsy
Procedure
Lead sponsor
Thomas Jefferson University
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 11, 2017 · Synced Sep 7, 2026, 6:53 PM EDT
Recruiting Phase 2 Interventional

Outpatient Administration of Teclistamab or Talquetamab for Multiple Myeloma

NCT05972135
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Teclistamab, Talquetamab, Tocilizumab, Oral Dexamethasone
Drug
Lead sponsor
SCRI Development Innovations, LLC
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
17
States / cities
Tucson, Arizona • Denver, Colorado • Newark, Delaware + 12 more
Source: ClinicalTrials.gov public record
Updated Apr 21, 2026 · Synced Sep 7, 2026, 6:53 PM EDT
Active, not recruiting Phase 1 Interventional Results available

Anti-CD19 CAR-T Cells With Inducible Caspase 9 Safety Switch for B-cell Lymphoma

NCT03696784
View directory record Official record
Conditions
Lymphoma, Lymphoma, B-Cell, Immune System Diseases, Immunoproliferative Disorders, Lymphatic Diseases
Interventions
iC9-CAR19 T cells, Bendamustine, Fludarabine, AP1903, Cyclophosphamide
Biological · Drug
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2040
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 30, 2026 · Synced Sep 7, 2026, 6:53 PM EDT
Terminated No phase listed Observational

Neurotoxicity in Primary Central Nervous System Lymphoma (PCNSL): An International Observational Study of Cognition in Long Term Survivors

NCT00710151
View directory record Official record
Conditions
Primary Central Nervous System Lymphoma (PCNSL)
Interventions
Not listed
Lead sponsor
OHSU Knight Cancer Institute
Other
Eligibility
18 Years to 75 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Apr 20, 2017 · Synced Sep 7, 2026, 6:53 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Phase 1 PK Study of XOMA 3AB

NCT01357213
View directory record Official record
Conditions
Botulism
Interventions
XOMA 3AB, Placebo
Drug · Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 45 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2013
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 4, 2014 · Synced Sep 7, 2026, 6:53 PM EDT
Completed Not applicable Interventional Results available

Advanced Neuroimaging Evaluation of CNS Changes Associated With Efavirenz Therapy Switch to an Raltegravir-based Regimen

NCT01978743
View directory record Official record
Conditions
HIV, HIV-associated Neurocognitive Disorder, Neurotoxicity
Interventions
Raltegravir
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 65 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 25, 2017 · Synced Sep 7, 2026, 6:53 PM EDT
Completed Phase 2 Interventional

Open Label, Safety, Tolerability and Efficacy of AFQ056 in Parkinson's Patients With L-dopa Induced Dyskinesias

NCT01173731
View directory record Official record
Conditions
Parkinson Disease, Dyskinesia, Drug-Induced, Levodopa
Interventions
AFQ056
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
Not listed
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
3
States / cities
Sunnyvale, California • Englewood, Colorado • Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Dec 22, 2020 · Synced Sep 7, 2026, 6:53 PM EDT
Completed Phase 3 Interventional Results available

EGb761 in Maintaining Mental Clarity in Women Receiving Chemotherapy for Newly Diagnosed Breast Cancer

NCT00046891
View directory record Official record
Conditions
Breast Cancer, Neurotoxicity
Interventions
Ginkgo Biloba, Placebo
Drug · Other
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older · Female only
Enrollment
226 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2015
U.S. locations
175
States / cities
Scottsdale, Arizona • Lompoc, California • Santa Barbara, California + 111 more
Source: ClinicalTrials.gov public record
Updated Jul 5, 2016 · Synced Sep 7, 2026, 6:53 PM EDT
Completed No phase listed Observational

Neurobehavioral Complications in Children Who Were Previously Treated With Steroids and Intrathecal Therapy for Acute Lymphoblastic Leukemia

NCT00085176
View directory record Official record
Conditions
Leukemia, Long-term Effects Secondary to Cancer Therapy in Children, Neurotoxicity, Psychosocial Effects of Cancer and Its Treatment
Interventions
management of therapy complications, psychosocial assessment and care
Procedure
Lead sponsor
Children's Oncology Group
Network
Eligibility
6 Years to 16 Years
Enrollment
286 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2011
U.S. locations
31
States / cities
Phoenix, Arizona • Loma Linda, California • Long Beach, California + 26 more
Source: ClinicalTrials.gov public record
Updated Jan 29, 2014 · Synced Sep 7, 2026, 6:53 PM EDT
Withdrawn Phase 2 Interventional

Siltuximab for Cytokine Release Syndrome Prophylaxis Prior to tx w/ Teclistamab in RRMM

NCT06352866
View directory record Official record
Conditions
Multiple Myeloma, Cytokine Release Syndrome, Refractory Multiple Myeloma, Immune Effector Cell Associated Neurotoxicity Syndrome
Interventions
Siltuximab, Teclistamab(FDA-approved)
Drug
Lead sponsor
Jack Khouri, MD
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 2, 2025 · Synced Sep 7, 2026, 6:53 PM EDT
Completed Phase 2 Interventional Results available

A Study of Itacitinib for the Prevention of Cytokine Release Syndrome Induced by Immune Effector Cell Therapy

NCT04071366
View directory record Official record
Conditions
Cytokine Release Syndrome
Interventions
Itacitinib, Immune effector cell therapy, Placebo, Yescarta
Drug · Biological
Lead sponsor
Incyte Corporation
Industry
Eligibility
12 Years and older
Enrollment
112 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
10
States / cities
Miami, Florida • Tampa, Florida • Boston, Massachusetts + 6 more
Source: ClinicalTrials.gov public record
Updated Mar 25, 2024 · Synced Sep 7, 2026, 6:53 PM EDT
Terminated Phase 2 Interventional Results available

A Safety and Efficacy Study of Defibrotide in the Prevention of Chimeric Antigen Receptor-T-cell-associated Neurotoxicity

NCT03954106
View directory record Official record
Conditions
DLBCL, Neurotoxicity Syndromes
Interventions
Defibrotide
Drug
Lead sponsor
Jazz Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
5
States / cities
Phoenix, Arizona • Baltimore, Maryland • Boston, Massachusetts + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 8, 2021 · Synced Sep 7, 2026, 6:53 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Cognitive Aftereffects of Neurotoxicity in Children and Young Adults With Relapsed/Refractory Hematologic Malignancies Who Receive CAR T-cell Therapy

NCT05237986
View directory record Official record
Conditions
Lymphoma, Leukemia
Interventions
Not listed
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
5 Years and older
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2028
U.S. locations
3
States / cities
Los Angeles, California • Bethesda, Maryland • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Aug 30, 2026 · Synced Sep 7, 2026, 6:53 PM EDT
Terminated Phase 1 Interventional

Ph I Study of Lithium During Whole Brain Radiotherapy For Patients With Brain Metastases

NCT00469937
View directory record Official record
Conditions
Brain and Central Nervous System Tumors, Cognitive/Functional Effects, Neurotoxicity, Solid Tumor
Interventions
lithium carbonate, cognitive assessment, quality-of-life assessment, radiation therapy
Drug · Procedure · Radiation
Lead sponsor
Vanderbilt-Ingram Cancer Center
Other
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
3
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Feb 27, 2012 · Synced Sep 7, 2026, 6:53 PM EDT